Avoid the Anti-Corruption "Blacklist:" Chinese Agency Guidance
On March 1, 2014, Circular No. 50 went into effect, promulgated to regulate the conduct of pharmaceutical and medical device companies that do business in China.
ChinaFood, Drugs, Healthcare, Life Sciences
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.